RxDoctor Payments Data

Lauren Gnagy, MD

Hospice and Palliative Medicine · Danville, INNPI 1609371632

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 26.6% of the total.

$413in general payments, 2019–2025

Across 21 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$110
  • GSK$71
  • AbbVie$50
  • Lilly USA, LLC$49
  • Exact Sciences$35
  • Vertex$23
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$413 in reported general payments places this provider in the 80th percentile of 32 hospice and palliative medicine providers in Indiana.

See all hospice and palliative medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$55,687
Medicare patients
108
Services billed
1,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$32,912
EliquisApixaban12$15,668
JardianceEmpagliflozin18$14,784
XareltoRivaroxaban13$8,295
Buprenorphine23$3,337
Bupropion XlBupropion Hcl20$2,889
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$1,140
Atorvastatin Calcium102$866
Levothyroxine Sodium89$803
Pantoprazole Sodium44$658
Rosuvastatin Calcium48$622
Gabapentin39$621
SynthroidLevothyroxine Sodium11$621
Ezetimibe16$576
Omeprazole33$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$110$32,91229 claims
Boehringer IngelheimJardiance$21$14,78418 claims
AbbVieSynthroid$50$62111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 hospice and palliative medicine providers in Indiana.

Other hospice and palliative medicine in Danville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →